Inhaled corticosteroids: Potency, dose equivalence and therapeutic index

British Journal of Clinical Pharmacology

Volumn 80, Issue 3, 2015, Pages 372-380

  Daley Yates, Peter T ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Corticosteroid; dose equivalence; inhaled; potency; therapeutic index

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; GLUCOCORTICOID RECEPTOR; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; PROTEIN BINDING;

ADRENAL SUPPRESSION; AEROSOL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; CORTICOSTEROID THERAPY; DOSE EQUIVALENCE; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG POTENCY; DRY POWDER; ELIMINATION HALF-LIFE; HUMAN; LIPOPHILICITY; LUNG FUNCTION; PARTICLE SIZE; PHARMACOLOGICAL PARAMETERS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; THERAPEUTIC INDEX; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; THERAPEUTIC EQUIVALENCE;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS; GLUCOCORTICOIDS; HUMANS; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, GLUCOCORTICOID; THERAPEUTIC EQUIVALENCY;

EID: 84940451754     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12637     Document Type: Article

References (54)

1. Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ,. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol 2003; 43: 1216-27.
2. Kelly HW,. Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 1998; 102: S36-51.
3. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, Fish JE, Israel E, Lazarus SC, Lemanske RF,. Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Am J Respir Crit Care Med 1996; 153 6: 1739-48.
4. Daley-Yates PT,. The clinical utility of pharmacokinetics in demonstrating bioequivalence of locally acting orally inhaled drugs. In: Respiratory Drug Delivery, eds, Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM,. Davis. River Grove: Healthcare International Publishing, 2010; 1: 273-83.
5. Hochhaus G, Mollmann H, Derendorf H, Gonzalez-Rothi RJ,. Pharmacokinetic and pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 1997; 37: 881-92.
6. Clark TJH,. Effect of beclomethasone dipropionate delivered by aerosol in patients with asthma. Lancet 1972; 1: 1361-4.
7. Daley-Yates PT,. Pharmacological aspects of glucocorticoid therapy. In: Exogenous Glucocorticoids in Paediatric Asthma, ed., Wolthers OD, Kerala: Transworld Research Network, 2007; 1-18.
8. Valotis A, Högger P,. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res 2007; 8: 54.
9. Brindley C, Mackie A.E, Falcoz C, Bye A,. Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy subjects. Clin Pharmacokinet 2000; 39 (Suppl. 1): 8.
10. Derendorf H,. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91 (Suppl. A): 22-8.
11. Salter M, Biggadike K, Matthews JL, West MR, Haase MV, Farrow SN, Uings IJ, Gray DW,. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007; 293: 660-7.
12. Rossios C, To Y, To M, Ito M, Barnes PJ, Adcock IM, Johnson M, Ito K,. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol 2011; 670: 244-51.
13. Jerre A, Sjölin P, Silberstein D, Wieslander E,. Cellular uptake and fatty acid esterification of budesonide and ciclesonide in protein-rich medium. Proc Am Thoracic Society 2006; 3: A73.
14. Boulet LP, Cowie RL, Negro RD, Brett W, Gold M, Marques A, Thorburn WS, Stepner NM, Robson R,. Comparison of once- with twice-daily dosing of fluticasone propionate in mild and moderate asthma. Can Respir J 2000; 7: 239-47.
15. Woodcock A, Bleecker ER, Busse WW, Lötvall J, Snowise NG, Frith L, Jacques L, Haumann B, Bateman ED,. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res 2011; 12: 160.
16. Daley-Yates PT,. Relationship between pharmacokinetic and aerodynamic particle size distribution properties for inhalers containing corticosteroids. Respiratory Drug Delivery 2014; 1: 163-72.
17. Masoli M, Holt S, Weatherall M, Beasley R,. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J 2004; 23: 552-8.
18. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R,. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001; 323: 253-6.
19. Molina DK, DiMaio VJ,. Normal organ weights in men: part II-the brain, lungs, liver, spleen, and kidneys. Am J Forensic Med Pathol 2012; 33: 368-72.
20. Mortimer KJ, Tata LJ, Smith CJP, West J, Harrison TW, Tattersfield AE, Hubbard RB,. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006; 61: 405-8.
21. Daley-Yates PT, Harker AJ, Taylor S, Daniel MJ,. Plasma protein binding of inhaled corticosteroids: reappraisal of its significance in systemic pharmacological activity. J Allergy Clin Immunol 2005; 115: S4.
22. Wolthers OD, Daley-Yates PT,. Inhaled glucocorticoids and hypothalamic-pituitary-adrenal axis function. In: Exogenous Glucocorticoids in Paediatric Asthma, eds Wolthers OD, Kerala: Transworld Research Network, 2007; 19- 34.
23. Daley-Yates PT, Pierre LN,. A physiologically based pharmacokinetic/pharmacodynamic model predicting cortisol suppression for inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163: A518.
24. Casale TB, Nelson HS, Stricker WE, Kenneth HR, Newman B,. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol 2001; 87: 379-85.
25. Wilson AM, McFarlane LC, Lipworth BJ,. Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. Am J Respir Crit Care Med 1997; 156: 1274-7.
26. Sorkness CA, LuForce C, Storms W, Lincourt WR, Edwards L, Rogenes PR,. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Clin Ther 1999; 2 1: 353-67.
27. Möllmann H, Wagner M, Krishnaswami S, Dimova H, Tang Y, Falcoz C, Daley-Yates PT, Krieg M, Stöckmann R, Möllmann AC, Derendorf H, Hochhaus G,. Single dose and steady state pharmacokinetic and pharmacodynamic evaluation of equipotent doses of inhaled fluticasone propionate and budesonide in healthy subjects. J Clin Pharmacol 2001; 41: 1329-38.
28. Daley-Yates PT, Bagen S, Tournant J, Pereira A,. Beclomethasone dipropionate chlorofluorocarbon and hydrofluoroalkane metered dose inhalers: relationship between systemic exposure, dose, fine particle mass and particle size in healthy volunteers. Eur Resp J 1999; 14 30: P1358.
29. Derom E, Van De Velde V, Marissens S, Engelstatter R, Vincken W, Pauwels R,. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005; 18: 328-36.
30. Chrousos GP, Ghaly L, Shedden A, Iezzoni DG, Harris AG,. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 2005; 128: 70-7.
31. Crim C, Pierre LN, Daley-Yates PT,. A review of the pharmacology and pharmacokinetics of fluticasone propionate and mometosone furoate. Clin Ther 2001; 23: 1339-54.
32. Daley-Yates PT, Derks MGM, Weeks AT, Mehta RS, Beerahee M, Sousa A,. Pharmacokinetics and pharmacodynamics of fluticasone propionate and mometasone furoate dry powder inhalers in healthy and asthmatic subjects. Am J Respir Crit Care Med 2005; 2: A354.
33. Allen A., The relationship between fluticasone furoate systemic exposure and cortisol suppression. Clin Pharmacokinet 2013; 52: 885-96.
34. FFA103096. A randomised, double blind, placebo controlled, incomplete block, five-way cross-over study to investigate the effect of one week repeat dosing of fluticasone furoate (GW685698X) and fluticasone propionate (FP) on twenty-four hour serum cortisol in healthy subjects. Study Period: October 2004-March 2005. Available at http://www.gsk-clinicalstudyregister.com (la st accessed 8 March 2015).
35. Brutsche MH, Brutsche IC, Munavvar M, Langley S, Masterson C, Daley-Yates PT, Brown R, Woodcock AA,. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in subjects with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: 556-61.
36. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003; 58 (Suppl. 1): i1-94.
37. Global Initiative for Asthma. Global strategy for asthma management and prevention 2014. Available at http://www.ginasthma.org (last accessed 8 March 2015).
38. Suarez E, Fang S, Abraham J, DiSantostefano RL, Stempel DA, Frith L, Barnes NC,. Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review. Thorax 2014; 69 (Suppl. 2): A182.
39. Hogger P, Rohdewald P,. Glucocorticoid receptors and fluticasone propionate. Rev Contemp Pharmacother 1998; 9: 501- 22.
40. Daley-Yates PT, Kunka RL, Shen YY, Andrews SM, Callejas S, Ng C,. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 2004; 60: 265-8.
41. Falcoz C, Oliver R, McDowall J, Ventresca GP, Bye A, Daley-Yates PT,. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet 2000; 39 (Suppl. 1): 9-15.
42. Taylor S, Harker A,. Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J Pharm Biomed Anal 2006; 41: 299-303.
43. Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Bart J,. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids, J Allergy Clin Immunol 1998; 101: S440-6.
44. Kaliner MA,. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: a comparison of ciclesonide and fluticasone propionate. Clin Ther 2006; 28: 319-31.
45. Mager DE, Jusko WJ,. Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. J Pharm Sci 2001; 91: 2442-51.
46. Agertoft L, Pedersen S,. Lung deposition and systemic bioavailability of fluticasone Diskus and budesonide Turbuhaler. Am J Respir Crit Care Med 2003; 168: 779-82.
47. Mackie AE, McDowall JE, Falcoz C, Ventresca GP, Bye A, Daley-Yates PT,. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy subjects. Clin Pharmacokinet 2000; 39 1: 23-30.
48. Thorsson L, Edsbacker S, Conradson TB,. Lung deposition from Turbuhaler is twice that from a pressurised metered dose inhaler P-MDI. Eur Respir J 1994; 7: 1839-44.
49. Agertoft L, Andersen A, Weibull E, Pedersen S,. Systemic availability and pharmacokinetics of nebulised budesonide in pre-school children with asthma. Arch Dis Child 1999; 80: 241-7.
50. Jeal W, Faulds D,. Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs 1997; 53: 257-80.
51. Derendorf H, Hochhaus G, Rohatagi S, Möllmann H, Barth J, Sourgens H, Erdmann M,. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995; 35: 302-5.
52. Barth J, Damoiseaux M, Möllmann H, Brandis KH, Hochhaus G, Derendorf H,. Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 1992; 30: 317-24.
53. Electronic Medicines Compendium. Datapharm Communications Limited,1999. Available at https://www.medicines.org.uk/emc (last accessed 8 March 2015).
54. FDA approved drug products. FDA center for drug evaluation and research, office of communications, division of online communications, 2014. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda (last accessed 8 March 2015).